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Identificationofmutationsat familial loci foramyotrophic lateral sclerosis (ALS)hasprovidednovel insights into
the aetiology of this rapidly progressing fatal neurodegenerative disease. However, genome-wide association
studies (GWAS) of the more common (∼90%) sporadic form have been less successful with the exception of
the replicated locus at 9p21.2. To identify new loci associated with disease susceptibility, we have established
the largest association study in ALS to date and undertaken a GWAS meta-analytical study combining 3959
newly genotyped Italian individuals (1982 cases and 1977 controls) collected by SLAGEN (Italian Consortium
for the Genetics of ALS) together with samples from Netherlands, USA, UK, Sweden, Belgium, France, Ireland
and Italy collected by ALSGEN (the International Consortium on Amyotrophic Lateral Sclerosis Genetics). We
analysed a total of 13 225 individuals, 6100 cases and 7125 controls for almost 7 million single-nucleotide
polymorphisms (SNPs). We identified a novel locus with genome-wide significance at 17q11.2 (rs34517613
with P 5 1.11 3 1028; OR 0.82) that was validated when combined with genotype data from a replication
cohort (P 5 8.62 3 1029; OR 0.833) of 4656 individuals. Furthermore, we confirmed the previously reported as-
sociation at 9p21.2 (rs3849943withP 5 7.69 3 1029;OR1.16). Finally,we estimated the contributionof common
variation toheritabilityof sporadicALSas∼12%usinga linearmixedmodelaccounting for allSNPs.Our results
provide an insight into the genetic structure of sporadic ALS, confirming that common variation contributes to
risk and that sufficiently powered studies can identify novel susceptibility loci.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a late-onset progressive
neurodegenerative disorder mainly affecting motor neurones.
ALS is the most common adult onset motor neurone disease
with prevalence of 5 per 100 000 and with family history, age
and male gender as the major risk factors (1–4). While familial
ALS is well characterized with several causative genes identified
to date, the genetic architecture of the more common sporadic
form is poorly understood. Previous genome-wide association
studies (GWAS) have identified several loci associated with
ALS risk such as DPP6, ITPR2, FGGY and UNC13a (5–11)
that have failed to be replicated in independent populations
(12–15). One exception is a locus on chromosome 9p21 (15)
that has been reliably replicated (16). At this locus, an expanded
hexanucleotide repeat in the C9orf72 gene has been recently
identified as the causative mutation in a large proportion of
familial (23–47%) as well as sporadic (5%) ALS cases
(17–20). This finding indicates that well-powered studies can
identify novel loci associated with ALS susceptibility. To dis-
cover further loci, we designed a large GWAS meta-analysis
with sufficient power to detect risk alleles with small effect
sizes as observed in other neurodegenerative and complex
diseases. There is evidence for a strong genetic component in
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sporadic ALS with heritability estimated to be 0.61 (95% CI:
0.38–0.78) in a combined study of 171 ALS twin pairs collected
by three independent studies from Britain and Sweden (21), so
we sought to estimate heritability derived from unrelated indivi-
duals and explained by common variation using GWAS data.
Phenotype variation in complex traits is owing to interactions
of genetic and environmental factors; thus, the quantification
of the genetic variance is relevant in the study of multifactorial
diseases. Heritability, the proportion of phenotype explained
by genetic variance, is typically estimated in closely related indi-
viduals such as twin pairs, but this can inflate estimates as a con-
sequence of epistatic interactions or shared environment (22,23).
In contrast, heritability explained by associated SNPs identified
in GWAS as passing-accepted thresholds of significance (typic-
ally P ≤ 5 × 1028) explains only a small fraction of the genetic
variation in most complex diseases. The difference between the
phenotypic variance explained by GWAS results and those esti-
mated in family studies is referred to as the ‘missing heritability
problem’ and possibly is explained by incomplete linkage dis-
equilibrium (LD) between genotyped SNPs and causal variants
and/or by the presence of gene-by-gene or gene-by-environment
interactions (22,23). We have estimated heritability of ALS con-
sidering all SNPs simultaneously regardless of their association
with ALS phenotype and compared this with heritability from
twin studies.
RESULTS
Association analyses
We analysed genotype raw data from eight independent studies
including 3959 newly genotyped Italian individuals (1982 cases
and 1977 controls) and 11 611 individuals (5195 cases and 6416
controls) from previously published studies. Full description of
the sample size included in this study is reported in Table 1 and
Supplementary Material, Table S1.
Raw data for each study were assessed for quality control (QC)
separately following the same criteria (see Supplementary Ma-
terial and Table S2 for full discussion). Population structure of
the individual cohorts was studied by means of principal compo-
nents analysis (PCA) with EIGENSTRAT software (24,25), and
outliers were identified by the projection of the first 10 principal
components (Supplementary Material, Methods and Fig. S1).
To achieve the maximal coverage, we imputed genome-wide
filtered originally genotyped data for each study (see Materials
and methods). Overall, the average number of inferred geno-
types was 8 342 920 SNPs varying proportionally to the original
genotyping platform. After filtering (Supplementary Material,
Methods), the eight datasets included genotype data for almost
7 million SNPs in 13 225 individuals (6100 cases and 7125 con-
trols) (Supplementary Material, Table S2). Cleaned imputed
genotypes were tested for association with ALS separately
using SNPTESTv2.4.0 (26), and the logistic regression analyses
were adjusted by the appropriate principal component axes esti-
mated in the individual cohorts (Supplementary Material,
Table S3). After genomic inflation control, we combined the lo-
gistic regression analysis results of each study in a meta-analysis
using the program METAL (27). We adopted the ‘standard error’
analysis scheme, which combines effect size estimates
(b-coefficients) across the studies weighted according to the
inverse of the corresponding standard errors. As a result of the
meta-analysis, we observed two loci reaching genome-wide
threshold of significance, rs3849943 with P ¼ 7.69×1029
(OR 1.16, 95% CI: 1.10–1.22; average posterior probability
(APP) 0.999; minor allele frequency (MAF) cases 0.268, con-
trols 0.238) on chromosome 9p21 and SNP rs34517613 with
P ¼ 1.11 × 1028 (OR 0.82, 95% CI: 0.76–0.87; APP 0.9279;
MAF cases 0.108, controls 0.129) on chromosome 17q11.2.
A third locus, rs1788776, at 18q11.2 was very close to
genome-wide significance threshold (P ¼ 7.67 × 1028, OR
0.87, 95% CI: 0.76–0.87; APP 0.9716; MAF cases 0.392, con-
trols 0.362) (Table 2, Figs. 1 and 2, Supplementary Material,
Fig. S2). With the exception of the locus on 9p21, loci previously
found to be associated with ALS risk (5–11) did not reach
genome-wide significance in our meta-analysis (Supplementary
Material, Table S4) although SNP rs12608932 (UNC13A) at
19p13.3 had not complete coverage across datasets as it failed
the QC threshold in the British dataset (Supplementary Material,
Fig. S3). Additionally, examination of these previously asso-
ciated loci in the Italian cohort as an independent replication
study only found evidence for association for the 9p21 locus,
and for the ITPR2 locus while significant, direction of effect is
the opposite to that reported in the original study (8) (Supple-
mentary Material, Fig S3). Only the ITPR2 locus showed signifi-
cant evidence for heterogeneity across the different cohorts of
European ancestry analysed here (Supplementary Material,
Table 1. Sample size and genotype platforms
Source Sample ancestry Sample size
(N)
Cases
(N)
Control
(N)
Genotyping Illumina
arrays
SNPs before
imputation
SNPs after
imputation
SLAGEN Consortium Italian 3959 1982 1977 660K 657366 8391895
UMC Utrecht Dutch 911 461 450 317K 317503 8328981
Utrecht, Umea˚, Leuven Dutch, Swedish, Belgian 2806 1364 1442 370K 317503 8372645
MGH, King’s College, Evry Northern American, British, French 3916 1710 2206 370K 307790 8370626
Beaumont Hospital, Dublin Irish 432 221 211 550K 561466 8268635
NIH publicly available, Coriell biobank Northern American 547 276 271 550K 555352 8325506
MND DNA bank and RADIANT study British 2252 663 1589 610K 471994 8372429
NIH publicly available Italian 747 500 247 550K 500002 8312642
Independent studies analysed in the combined international meta-analysis were genotyped on different type of Illumina platforms. Italian data were collected by the
SLAGEN Consortium (Italy) and the Dutch, Swedish, French, Belgian, Irish and North American, and Italian raw data were collected by the International
ALS-GWAS Consortium (ALSAGEN). British cases were collected by UK National MND Bank samples and British controls by the RADIANT study (DeCC,
BACCs) and NIH publicly available data from Coriell biobank (www.coriell.org).
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Table 2. ALS-GWAS meta-analysis results
Chromosome SNP Position A1 A2 APP Info MAF_ALS MAF_CONT OR P-value Direction Low 95% CI Up 95% CI
9 rs3849943 27533382 C T 1 0.999 0.268 0.238 1.166 7.69E209 +22+++++ 1.107 1.228
9 rs3849941 27528948 A G 0.993 0.986 0.266 0.236 1.166 9.54E209 2++22222 1.106 1.229
9 rs2477523 27526894 T A 0.997 0.992 0.269 0.239 1.163 1.06E208 2++22222 1.104 1.225
9 rs2453555 27553868 G A 0.995 0.988 0.27 0.239 1.163 1.07E208 2++22222 1.104 1.225
17 rs34517613 23634379 C T 0.922 0.734 0.108 0.129 0.822 1.11E208 ++++++++ 0.769 0.879
17 rs12937920 23614784 C T 0.951 0.854 0.125 0.149 0.83 1.24E207 ++++++++ 0.775 0.889
17 rs9909055 23620255 C T 1 1 0.217 0.249 0.857 1.98E207 ++++++++ 0.809 0.908
17 rs16964203 23606837 A C 0.978 0.954 0.224 0.257 0.86 2.55E207 22222222 0.812 0.911
17 rs2292633 23599507 G A 0.956 0.906 0.221 0.254 0.86 2.82E207 ++++++++ 0.812 0.911
17 rs35714695 23743915 G A 0.973 0.934 0.169 0.192 0.845 3.21E207 ++++++++ 0.792 0.901
17 rs739439 23747949 C T 0.994 0.984 0.169 0.193 0.842 3.97E207 ++++++++ 0.788 0.900
17 rs9900311 23619534 G A 0.997 0.992 0.219 0.252 0.858 4.58E207 ++++++++ 0.808 0.911
18 rs1788776 19498035 G A 0.971 0.947 0.392 0.362 0.872 7.67E208 +++++2++ 0.830 0.917
18 rs1629335 19475137 C G 0.956 0.927 0.383 0.353 0.874 1.00E207 22222222 0.832 0.918
18 rs62093304 19489968 T C 0.979 0.96 0.389 0.36 0.875 2.09E207 22222+22 0.832 0.920
18 rs12957850 19487958 G T 0.988 0.976 0.408 0.382 0.878 2.64E207 +++++2++ 0.836 0.923
18 rs1652373 19482645 G T 1 1 0.409 0.382 0.877 2.66E207 +++++2 0.834 0.922
18 rs12606211 19499478 C T 0.979 0.961 0.408 0.381 0.88 3.29E207 +++++2++ 0.838 0.924
18 rs1711468 19498537 C A 0.97 0.945 0.41 0.384 0.882 4.16E207 +++++2++ 0.840 0.926
Summary of the most significant associated SNPs in the international ALS-GWAS meta-analysis from imputed genotypes. Meta-analysis (METAL) was performed weighting by theb-coefficient estimates and
the inverse of their corresponding standard errors. Effect size of reference allele A1 is expressed with positive and negative symbols; symbols ‘+’ and ‘2’ indicate the direction of the effect size (beta values from
regression), where a plus symbol means that increasing frequency of allele A1 is correlated with increasing trait values and vice versa.
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Table S5). Further larger studies are needed to confirm the role of
these loci in ALS susceptibility.
As inclusion of non-confounding covariates such as gender
and age can significantly reduce power to identify truly asso-
ciated variants particularly when the disease prevalence is low
(,1%), we have not included non-confounding covariates in
logistic regression analyses presented here (28). In confirmation
of our approach, the most significant SNPs (P ≤ 1 × 1025)
mapping in the two candidate loci at 17q and 18q showed no
gender-by-SNP interaction in multi regression analysis (see
Materials and methods).
For these loci, we searched for secondary signals by perform-
ing logistic regression conditioning upon the most associated
SNPs under an additive model. There was no evidence of
independent SNPs in any of these regions (Supplementary Ma-
terial, Table S6). As the international meta-analysis included
samples from Northern and Southern Europe, we tested the
most associated SNPs for genetic heterogeneity quantifying
the effect of the degree of variation between studies (Supplemen-
tary Material, Methods). We observed no significant heterogen-
eity in the distribution of allele frequencies between European
populations for these SNPs (Supplementary Material, Table S7).
As additional evidence, we tested the candidate loci at 17q and
18q in a novel independent replication cohort of 2074 cases and
2556 controls collected in Italy, Netherlands and Germany (see
full description in the Supplementary Material, Methods and
Table S8). For each locus, we selected two variants, the most
associated in the GWAS meta-analysis (imputed data) and
Figure 1.Manhattan plot of the international ALS meta-analysis. Scatter plot of chromosome position (x-axis) against –log10 GWAS meta-analysis P-values (y-axis)
from imputed data. The threshold of genome-wide significance (P ¼ 5 × 1028) is indicated as a horizontal red line. At locus 9p21.2, 18 SNPs close to Corf72 gene lie
above the red line (most significant SNP is rs3849943 with P ¼ 7.69 × 1029). Locus 17q11.2 shows SNP rs34517613 (P ¼ 1.11 × 1028) to be significantly asso-
ciated. SNP rs1788776 at 18q11.2 is very close to the threshold of significance with P ¼ 7.67 × 1028. Manhattan plot was produced using ggplot2 package in R.
Figure 2.Regional association plots of the associated loci. LD structure of the three regions associated with ALS in the international GWAS meta-analysis. For each
plot, the 2log10 P-values (left y-axis) of SNPs are shown according to their chromosomal positions (x-axis); the genetic recombination rates are shown on the right
y-axis.2log10 P-values are shown for both genotyped and imputed SNPs distributed in a 0.8-megabase genomic region. The top SNP of each region is indicated as a
diamond, and SNPs colour reflects LD correlation (r2). (A) locus at 9p21, (B) 17q11.2 and (C) 18q11.2. LD plots were generated by LocusZoom v1.1.
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combined joint analysis (original genotype data) (Supplemen-
tary Material, Table S9). We found suggestive evidence for asso-
ciation in the independent replica analysis for SNP rs34517613
at 17q (P ¼ 0.055; OR 0.89, 95% CI: 1.00–0.78) and when com-
bined in meta-analysis with the full GWAS data, the association
identified in the discovery sample became more significant
(Pcombined ¼ 8.62 × 1029; OR 0.833, 95% CI: 0.891–0.778).
We found no additional evidence for association at the
18q11.2 locus (Supplementary Material, Table S10).
The locus at 17q11.2 is gene rich with a number of plausible
candidates (Fig. 2). In an effort to refine associations at this
locus and at 18q11.2, we searched for non-synonymous SNPs
in LD (r2 ≥ 0.4) with our two lead signals to identify possible
functional variants that explained the associations with ALS
risk. No non-synonymous variants were found in LD at the
17q11.2 locus; however, three SNPs, rs739439 (r2 ¼ 0.416) in
the 3′ untranslated region, the intronic SNPs rs35714695 (r2 ¼
0.457) and rs34660379 (r2 ¼ 0.412) within the SARM1 (sterile
alpha and TIR-containing motif 1) gene were in LD (Table 2,
Fig. 2).
At the suggestive 18q11.2 locus, the lead SNP rs1788776 was
only in strong LD with SNPs in the ANKRD29 gene (Fig. 2), an
ankyrin repeat domain-containing protein of undetermined func-
tion, these included missense SNPs (rs12956232, r2 ¼ 0.78;
rs1788758, r2 ¼ 0.78; rs12960692, r2 ¼ 0.74; rs11662113,
r2 ¼ 0.53) (Table 2, Fig. 2).
Next, we looked for cis eQTL (expression quantitative trait
loci) in LD with our lead SNPs. All SNPs in LD (r2 ≥ 0.2)
with rs34517613 and rs1788776 were analysed for association
with cis eQTL using several publicly available eQTL databases
(Supplementary Material), but none reached the P-value thresh-
old for significance. This should not be considered conclusive as
expression data from central nervous system tissues are still
rather limited across eQTL databases and further studies
should be carried out.
Contribution of C9orf72 to chromosome 9p21 association
signal
As chromosome 9p21 was found to be strongly associated in our
meta-analysis, we further investigated the contribution of ALS
sporadic cases that also carry the expanded hexanucleotide
repeat in the C9orf72 gene to this association. Information
about carriers of the pathologic expansion in C9orf72 gene
was available for 2287 of 6100 (37.3%) ALS cases from the
Italian, Dutch and British studies included in the meta-analysis.
The frequency of the expanded repeats carriers in the sporadic
cases we have analysed progressively decreased as you
proceed from Northern to Southern Europe ranging from 8 to
4.7%, respectively, in the British and Italian patients (see Mate-
rials and methods, Supplementary Material, Table S10). Our
results confirm data previously reported (17–20). We performed
a meta-analysis of this sample subset (2287 sporadic cases and
4162 controls) including and excluding cases (n ¼ 144) with
the expanded hexanucleotide repeat. Significant association
of SNP rs3849943 decreased from P ¼ 7.72 × 1025 to
P ¼ 0.052 when the carriers were excluded from the logistic
regression analysis, confirming that the association of 9p21
locus was largely dependent on carriers of the C9orf72 expan-
sion (Supplementary Material, Fig. S4).
Heritability estimation
We used the Genome-wide Complex Trait Analysis (GCTA)
method (29) to quantify additive genetic variance (narrow
sense heritability) explained by all common SNPs regardless
of their association with disease. GCTA uses a linear mixed-
effect model that includes a random effect to estimate the poly-
genic component of trait variation (29). We performed GCTA
analysis on 13 225 individuals (6100 ALS cases and 7125 con-
trols) whose pair wise relationship was estimated to be ,0.05
(PI_HAT) and used a restricted maximum likelihood (REML)
algorithm to estimate the variance explained by imputed SNPs
data. Analyses were carried out separately in the eight cohorts
using a more stringent quality control threshold for imputed
SNPs (MAF.0.01, posterior probability.0.9 and information
measure.0.8) (see Materials and methods, Supplementary Ma-
terial, Table S2) under the assumption of an ALS prevalence of 5
per 100 000. Heritability estimates were similar (11.5%) for
all cohorts (Supplementary Material, Table S12) and were com-
bined in meta-analysis modelled for random effects and
weighted by sample size. The summary heritability was 0.119
(95% CI: 0.110–0.127) (Fig. 3).
Exclusion of the chromosome 9p21 locus did not affect herit-
ability estimates. As ALS is a disease of aging and age is increas-
ing in the human population, an increase in the prevalence of ALS
can be predicted. Consequentially, the true prevalence of ALS
may be higher than that used in our analysis. We have therefore
calculated heritability over a range of prevalences, but for all pre-
valences, estimation of heritability attributable to common vari-
ation does not exceed 0.25 (Supplementary Material, Fig. S5).
DISCUSSION
In this study, we present the largest GWAS meta-analysis to date
in ALS. Overall, we analysed 13 225 individuals with sufficient
Figure 3.Heritability estimate across ALS-GWA studies. Heritability estimated
in eight independent ALS cohorts. Forest plot shows heritability value and con-
fidence interval (95%) calculated in each study at the reported prevalence of
5/100 000. Black boxes indicate the single studies, and box sizes are proportional
to the sample (N). Grey bars specify lower and upper limit of 95% confidence
interval.
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power to capture allelic association with small effects and low
MAF. The novel associated SNP rs34517613 at 17q11.2 was
confirmed when genotype data from the independent replication
cohort were combined in meta-analysis with full GWAS data.
We have also replicated the 9p21 locus at genome-wide signifi-
cance; this locus was also identified by linkage studies of familial
ALS patients and by analogy it may be that there is a correspond-
ing familial locus for the 17q11.2 locus identified here, though
we are not aware of any reports.
The lead SNP at this locus was in LD with three SNPs in the
SARM1 gene. Interestingly, SARM1 orthologues, dSarm in Dros-
ophila melanogaster and Sarm1 in mice, have been recently
found to play a direct role in an axonal self-destruction
pathway, a mechanism known as Wallerian degeneration,
which shares morphological similarities with the axon dying-
back degeneration observed in ALS and in other neurodegenera-
tive pathologies (30,31). As axonal degeneration is an early
feature of ALS progression, a mouse model for familial ALS,
SOD1G93A, was crossed with the WldS mouse, a spontaneous
mutant with phenotype of prolonged survival of injured axons
because of a chromosomal rearrangement that disrupts two
genes, Ube4b and Nmnat1. In the SOD1G93A/WldS, the progres-
sion of axonopathies was attenuated, suggesting that the Waller-
ian pathway could be involved in the axon loss observed in ALS
(32,33).
We estimated the heritability of ALS owing to common vari-
ation as 12% based on a prevalence of 5 per 100 000 (1,2), al-
though the true prevalence of ALS may be higher as consequence
of increasing age in the human population as discussed earlier.
We have also only considered autosomal SNPs and additional
variance may be encoded on the X chromosome. Twin studies es-
timate heritability owing to all genetic variation including rare
monogenic forms of the disease, whereas we have estimated her-
itability as a consequence of common polymorphisms either dir-
ectly typed or imputed. The difference between heritability
estimated from twin studies and from analysis of common
SNP polygenic variation suggests a substantial role for variation
not captured by genome-wide association studies.
Our estimate for the heritability of ALS explained by com-
mon variation is lower than that for other late-onset neurodegen-
erative diseases. Using similar approaches, heritability for
late-onset Parkinson’s disease was 0.31 (34), 0.24 for late-onset
Alzheimer’s disease and 0.30 for multiple sclerosis (35). These
differences in heritability owing to common variants are
reflected in the difficulty in identifying genome-wide significant
loci for ALS compared with these diseases. For example, a two-
stage GWA study of Parkinson’s disease with a stage 1 sample
size of 6000 individuals identified two strong association
signals (36), and a study of Alzheimer’s disease with a similar-
sized stage 1 sample identified two loci additional to the well-
replicated APOE locus (37). In comparison with these studies,
our combined sample size is .13 000 individuals, suggesting
that the genetic architecture of ALS may be different from
other more common neurodegenerative diseases. A recent
study of ALS in a Han Chinese population identified two loci
of genome-wide significance in a combined sample of 5 000
(38); strikingly these loci were not replicated in populations of
European ancestry, nor in the combined meta-analysis reported
here. This suggests there may be considerable heterogeneity in
ALS risk loci across different ethnicities; in support of this, the
expanded repeat in the C9orf72 gene has been reported to be
infrequent in Asian populations (39,40).
In conclusion, we have identified a novel locus for sporadic
ALS risk at 17q11.2, but not replicated the suggestive evidence
for a second locus at 18q11.2 and confirmed the association at
9p21 with the expanded hexanucleotide repeat in the C9orf72
gene. Furthermore, we provide evidence from our heritability esti-
mates that furthercommonvariationaffectingALSriskremains to
be detected by current GWAS platforms and with larger cohorts
but that denser genome-wide assays and next generation sequen-
cing technologies are required to detect rarer variation.
MATERIALS ANDMETHODS
Participating individuals
The discovery sample consisted of a novel Italian cohort col-
lected by the Italian Consortium for the Genetics of ALS
(SLAGEN) and seven independent published studies collected
by ALSGEN, The International Consortium on Amyotrophic
Lateral Sclerosis Genetics (5–11,15,16). All patients fulfilled
the El Escorial revised criteria for ALS (41). Written informed
consent according to the Declaration of Helsinki was obtained
from all patients and healthy subjects participating to this
study. Local ethical committees for each participating institution
approved these studies. All samples across the eight datasets
were of European ancestry, and a full description of demograph-
ic details is reported in the Supplementary Material, Table S1.
All patients with family history of ALS or carrying Mendelian
risk genes were excluded from analyses. Screening for the
expanded hexanucleotide repeat in the C9orf72 gene were
performed subsequently; information of mutation carries
was available for a subset of cases included in the Italian,
Dutch and British cohorts (see Supplementary Material for full
description).
A replication sample of 4630 individuals (2074 cases and
2556 controls) was collected across Italy, The Netherlands and
Germany using the same diagnostic criteria (see Supplementary
Material, Table S8).
Genotyping procedures
Samples from the individual cohorts were genotyped on differ-
ent Illumina beadchips (Illumina, CA, USA) as shown in
Table 1. Additional SNPs were genotyped in the replication
phase by PCR-based KASP technique by the KBioscience
(UK) facility for the Italian samples (622 cases and 971 controls)
or by TaqMan_2013 PCR method for the Dutch (877 cases and
1226 controls) and German samples (575 cases and 359 controls)
(Supplementary Material). Cross-validation between method-
ologies showed 100% concordance.
Statistical analysis
Quality control and meta-analysis of imputed data
Before imputation analysis QC of samples and markers was per-
formed separately in the eight studies using the PLINK software
package (42). A detailed description of QC procedure is reported
in the Supplementary Material and Table S2. Genotype data
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from British cases and controls were merged and analysed as
single cohort as fully described in the Supplementary Material
and Table S2.
Ancestry differences between individuals within each cohort
were detected by PCA. Principal component axes were gener-
ated by genotypes of a genome-wide subset of LD-independent
SNPs using EIGENSTRAT software (24,25), and outliers iden-
tified by the first 10 principal components (PCs) were removed.
The number of significant principal components was estimated
by Tracy–Widom distribution using the program TW statistic
(25) and included as covariates in the logistic regression analyses
of each study for population stratification control. Scatter plots of
PC1 and PC2 showed no evidence of substructure between cases
and controls within the single cohorts (Supplementary Material,
Fig. S1). As an example, Supplementary Material, Figure S5
shows the population structure of the novel Italian cohort by
the projection of the first two PC axes.
After QC, original genotype data of each study were tested for
genomic inflation and lambda estimates resulted to be minimal
(l(gc) , 1.02). Individual datasets were imputed genome wide
separately using the IMPUTE.v2 program (43,44), which
employs combined reference panels of known phased haplo-
types provided by HapMap 3 (Feb 2009), 1000 Genomes
Project (Mar 2010) (NCBI build 36 coordinates) and the
study’s sample genotypes (Supplementary Material). In each
cohort, imputed genotypes were tested for association with
ALS status by logistic regression analysis (SNPTESTv2.4.0) in-
cluding the specific PCs as confounder covariates to control
population stratification. For each test, statistic spurious associa-
tions and genomic inflation were controlled by plotting the
observed quantiles versus the expected ones in Q–Q plots and
by factor l(gc) estimate (Supplementary Material, Fig. S7 and
Table S3) (R package software).
SNP statistic data were filtered for uncertainty of inferred gen-
otypes according to posterior probability (APP) of .0.9 and stat-
istical information of allele frequency (info) of .0.4 (26). The
average number of SNPs filtered out in each dataset was 1.47
million (Supplementary Material, Table S2). Finally, filtered
SNP tables were combined in a meta-analysis and analysed with
the program METAL (27), applying the standard error scheme
option that weights effect size estimates, or b-coefficients, using
the inverse of the corresponding standard errors. The z-scores
were calculated from the P-values of each study with the sign of
the z-scores indicating the direction of allelic effect in that study
(z. 0 for odds ratio.1). Meta-analysis was performed applying
the fixed-effects model that does not account for study heterogen-
eity; therefore, heterogeneity was quantified by the Cochran’s stat-
istic (Q) and I2 (METAL). P-values were estimated by comparing
the statistic with a X2 distribution (N—1 ‘degrees of freedom’,
N ¼ number of studies) (Supplementary Material and Table S5
and S7) (45,46). Meta-analysis was repeated stratifying by
gender and testing for the gender-by-SNP interaction as described
in Supplementary Material.
For the independent replication cohort, logistic regression
analyses (SNPTESTv2.4.0) were performed separately in the
Italian, Dutch and German samples and then combined in
meta-analysis (METAL) applying standard error scheme as
described earlier. Next, statistic tables of the three novel replica-
tion samples were combined with the discovery sample in a final
meta-analysis (METAL).
Power calculation
The final meta-analysis cohort had 99.99% power to detect
allelic association with an odds ratio (OR) of 1.2 and MAF of
0.25 at genome-wide significance (P ¼ 5 × 1028). For low-
frequency variants with MAF ranging from 0.01 to 0.04 and of
small effect (OR , 1.5), there was low power to capture variants
with MAF 0.01, whereas for SNPs with MAF 0.02 power ranged
from 60 to 98% for alleles with OR of 1.3 and 1.4, respectively
(Supplementary Material, Fig. S8).
Screening of expanded repeats in C9orf72 gene
Hexanucleotide repeat expansion data for the C9orf72 gene were
available for the Italian, Dutch and British cases (Supplementary
Material, Table S10). As previously reported, carriers were
defined as individuals with a range of the GGGGCC repeats of
.23 units (17–20). We performed conditional logistic regres-
sion analysis on a subset of 2287 screened cases and 4162 con-
trols including and excluding pathologic expansions carriers
(n ¼ 144).
Estimation of the genetic variance tagged by all SNPs
We used GCTA software (29) to estimate the proportion of ALS
phenotypic variance explained by autosomal SNPs distributed
genome wide. Genetic relationships between pairs of individuals
were calculated separately in the eight cohorts where all samples
were previously tested for cryptic relatedness and excluded if the
proportion of IBD (identical-by-descent) estimate was .0.05
(Supplementary Material, Table S2). We estimated the genetic
relationship matrix (GRM) including imputed genotypes filtered
by MAF .0.01, posterior probability .0.9 and information
measure .0.8. Filtered genotype data were submitted to GRM
analysis, and GRMs output data were used in the REML analysis.
In each dataset, REML analysis was carried out by fitting the spe-
cific principal components (Supplementary Material, Table S3)
as covariates to control for possible population stratification. The
variance estimate was transformed from the observed scale
(V(1)/Vp) to a scale of liability (V(1)/Vp_L) by specifying a
disease prevalence for ALS of 5 per 100 000 persons (1,2).
The variance estimate of each cohort was combined by
random effects meta-analysis weighted by sample size using
the library rmeta in R toolset.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
DATA AVAILABILITY
Data were accessed by formal request to the consortia members.
The complete summary meta-analysis data (SNP, genomic pos-
ition, odds ratio and P-value) are freely available at the ALSOD
website (http://alsod.iop.kcl.ac.uk/) in a searchable format (47).
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